ATRA vs. ORIC, MDWD, BTMD, LRMR, CGC, CRGX, ACIU, NMRA, FDMT, and NLTX
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), MediWound (MDWD), biote (BTMD), Larimar Therapeutics (LRMR), Canopy Growth (CGC), CARGO Therapeutics (CRGX), AC Immune (ACIU), Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.
Atara Biotherapeutics vs. Its Competitors
Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.
Oric Pharmaceuticals has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.
95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Oric Pharmaceuticals presently has a consensus price target of $18.57, indicating a potential upside of 66.04%. Atara Biotherapeutics has a consensus price target of $20.00, indicating a potential upside of 105.87%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.
In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 3 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.73 beat Atara Biotherapeutics' score of 0.62 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.
Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -7.83%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.
Summary
Oric Pharmaceuticals beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATRA) was last updated on 7/17/2025 by MarketBeat.com Staff
